Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

Yuang Wei; Xinglin Chen; Xiaohan Ren; Bao Wang; Qian Zhang; Hengtao Bu; Jian Qian; Pengfei Shao

doi:10.3389/fgene.2021.680369

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

Front Genet. 2021 Jul 9:12:680369. doi: 10.3389/fgene.2021.680369. eCollection 2021.

Authors

Yuang Wei¹, Xinglin Chen¹, Xiaohan Ren¹, Bao Wang¹, Qian Zhang¹, Hengtao Bu¹, Jian Qian¹, Pengfei Shao¹

Affiliation

¹ Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Abstract

Background: Antiangiogenic agents that specifically target vascular endothelial growth factor receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for metastatic clear cell renal cell carcinoma (ccRCC) patients. However, most patients eventually show no responses to the targeted drugs, and the mechanisms for the resistance remain unclear. This study is aimed to identify pivotal molecules and to uncover their potential functions involved in this adverse event in ccRCC treatment.

Methods: Two datasets, GSE64052 and GSE76068, were obtained from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were identified using the limma package in R software. The gene set enrichment analysis (GSEA) was conducted using clusterProfiler package. A protein-protein interaction (PPI) network was built using the STRING database and Cytoscape software. Kaplan-Meier survival curves were plotted using R software. qRT-PCR and Western blotting were used to detect the MX2 and pathway expression in RCC cell lines. Sunitinib-resistant cell lines were constructed, and loss-of-function experiments were conducted by knocking down MX2. All statistical analyses were performed using R version 3.6.1 and SPSS 23.0.

Results: A total of 760 DEGs were derived from two datasets in GEO database, and five hub genes were identified, among which high-level MX2 exhibited a pronounced correlation with poor overall survival (OS) in sunitinib-resistant ccRCC patients. Clinical correlation analysis and Gene Set Variation Analysis (GSVA) on MX2 showed that the upregulation of MX2 was significantly related to the malignant phenotype of ccRCC, and it was involved in several pathways and biological processes associated with anticancer drug resistance. qRT-PCR and Western blotting revealed that MX2 was distinctly upregulated in sunitinib-resistant RCC cell lines. Colony formation assay and Cell Counting Kit-8 (CCK8) assay showed that MX2 strongly promoted resistant capability to sunitinib of ccRCC cells.

Conclusion: MX2 is a potent indicator for sunitinib resistance and a therapeutic target in ccRCC patients.

Keywords: Prognosis; TKIs; antiangiogenic therapy; clear cell renal cell carcinoma; drug resistance; human myxovirus resistance protein 2; sunitinib resistance.